Alberto Chiarugi

ORCID: 0000-0003-1022-2435
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • PARP inhibition in cancer therapy
  • Migraine and Headache Studies
  • Tryptophan and brain disorders
  • Trigeminal Neuralgia and Treatments
  • Cell death mechanisms and regulation
  • Stress Responses and Cortisol
  • Toxin Mechanisms and Immunotoxins
  • Sirtuins and Resveratrol in Medicine
  • Calcium signaling and nucleotide metabolism
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Mitochondrial Function and Pathology
  • Neuroscience and Neuropharmacology Research
  • Multiple Sclerosis Research Studies
  • Mediterranean and Iberian flora and fauna
  • Histone Deacetylase Inhibitors Research
  • Integrated Circuits and Semiconductor Failure Analysis
  • Neuroendocrine regulation and behavior
  • Advanced Glycation End Products research
  • Adenosine and Purinergic Signaling
  • Circadian rhythm and melatonin
  • Autophagy in Disease and Therapy
  • Cancer, Hypoxia, and Metabolism
  • Cardiac electrophysiology and arrhythmias
  • Psychosomatic Disorders and Their Treatments
  • NF-κB Signaling Pathways

University of Florence
2016-2025

Azienda Ospedaliero-Universitaria Careggi
2016-2025

Queen Mary University of London
2013

Leibniz Institute on Aging - Fritz Lipmann Institute (FLI)
2009

Friedrich Schiller University Jena
2009

University of Brescia
2008

University of Milan
2008

IRCCS Istituto Auxologico Italiano
2008

Mario Negri Institute for Pharmacological Research
2008

Marche Polytechnic University
2008

To evaluate the efficacy, safety, and tolerability of noninvasive vagus nerve stimulation (nVNS; gammaCore; electroCore, LLC, Basking Ridge, NJ) for acute treatment migraine in a multicenter, double-blind, randomized, sham-controlled trial.A total 248 participants with episodic with/without aura were randomized to receive nVNS or sham within 20 minutes from pain onset. Participants repeat if had not improved 15 minutes.nVNS (n = 120) was superior 123) freedom at 30 (12.7% vs 4.2%; p 0.012)...

10.1212/wnl.0000000000005857 article EN cc-by-nc-nd Neurology 2018-06-15

Mitochondria and cytochrome c release play a role in the death of neurons glia after cerebral ischemia. In present study, we investigated whether BID, proapoptotic promoter caspase 8 substrate, was expressed brain, activated an ischemic insult vivo vitro , contributed to cell death. We detected BID cytosol mouse brain primary cultured demonstrated, by using recombinant 8, that neuronal also is substrate. After 2 h oxygen/glucose deprivation, cleavage concurrent with activation but before 3...

10.1073/pnas.261323298 article EN Proceedings of the National Academy of Sciences 2001-12-11

Pharmacological manipulation of gene expression is considered a promising avenue to reduce postischemic brain damage. Histone deacetylases (HDACs) play central role in epigenetic regulation transcription, and inhibitors HDACs are emerging as neuroprotective agents. In this study, we investigated the effect HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) on histone acetylation control ischemic mouse brain. We report that H3 was constitutively present at specific lysine residues neurons...

10.1124/mol.106.027912 article EN Molecular Pharmacology 2006-08-31

High mobility group proteins are chromatin binding factors with key roles in maintenance of nuclear homeostasis. The evidence indicates that extracellularly released high box 1 (HMGB1) protein behaves as a cytokine, promoting inflammation and participating to the pathogenesis several disorders peripheral organs. In this study, we have investigated expression levels relocation dynamics HMGB1 neural cells, well its neuropathological potential. We report is culture media neurons astrocytes...

10.1111/j.1471-4159.2007.04788.x article EN Journal of Neurochemistry 2007-06-29

Abstract Excessive release of proinflammatory products by activated glia causes neurotoxicity and participates in the pathogenesis neurodegenerative disorders. Recently, poly(ADP‐ribose) polymerase‐1 (PARP‐1) has been shown to play a key role nuclear factor kappa B (NF‐κB)‐driven expression inflammatory mediators during neuroimmune response. Here we report novel finding that enzymatic activity PARP‐1 promotes, an β‐nicotinamide adenine dinucleotide‐dependent fashion, DNA binding NF‐κB...

10.1046/j.1471-4159.2003.01684.x article EN Journal of Neurochemistry 2003-04-01

During the last several years, evidence that various enzymes hydrolyze NAD into bioactive products prompted scientists to revisit or design strategies able increase intracellular availability of dinucleotide. However, plasma membrane permeability and mitochondrial origin dinucleotide still wait be clearly defined. Here, we report contents increased upon exposure cell lines primary cultures exogenous (eNAD). precursors could not reproduce effects eNAD, they were found in incubating medium...

10.1124/mol.111.073916 article EN Molecular Pharmacology 2011-09-14

Criteria, including clinical features and effective outcomes, for access persistence of novel but costly treatments may vary between countries, thus affecting the health patients. Monoclonal antibodies against calcitonin gene-related peptide pathway (anti-CGRP mAbs) migraine treatment are currently prescribed following strict criteria. The aim was to assess effectiveness safety three anti-CGRP mAbs (erenumab, galcanezumab, fremanezumab) in consecutive resistant chronic patients presenting at...

10.1007/s40263-021-00893-y article EN cc-by-nc CNS Drugs 2022-02-01

(1930). Apomissia in “Ochna Serrulata„ Walp. Giornale botanico italiano: Vol. 37, No. 1, pp. 1-250.

10.1080/11263503009439741 article EN Giornale botanico italiano 1930-01-01

Guidelines for migraine prophylaxis suggest stopping medication after 6-12 months to reevaluate treatment appropriateness. The Italian Medicines Agency set a mandatory regulation stop anti-calcitonin gene related protein (CGRP) pathway monoclonal antibody (anti-CGRP mAb) treatments 3 12 of treatment. Herein, the effects discontinuation and retreatment anti-CGRP mAbs in resistant chronic patients are assessed, evaluating predictive factors sustained response.This was monocentric prospective...

10.1111/ene.15260 article EN European Journal of Neurology 2022-01-31

A pharmacological class effect was initially proposed for monoclonal antibodies against the calcitonin gene related peptide pathway. However, preliminary evidence shows that switching patients who were non-responding to one antibody another could provide some benefit. Herein, we assess treatment response an anti-calcitonin peptide/receptor in have failed respond peptide/ligand and vice versa. In addition, select non-responders first anti- by three or five more stringent...

10.1177/03331024231160519 article EN cc-by-nc Cephalalgia 2023-03-14

Abstract Nitric oxide (NO) generated from inducible NO synthase (iNOS) participates in immune and inflammatory responses many tissues. The donor glyceryl trinitrate (GTN) provokes delayed migraine attacks when infused into migraineurs also causes iNOS expression inflammation within rodent dura mater. Sodium nitroprusside, an as well, increases expression. Because are potential therapeutic targets, we examined transcriptional regulation of following GTN infusion the consequences its...

10.1002/ana.10159 article EN Annals of Neurology 2002-03-19

To obtain further information on time course and mechanisms of cell death after poly(ADP-ribose) polymerase-1 (PARP-1) hyperactivation, we used HeLa cells exposed for 1 h to the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine. This treatment activated PARP-1 caused a rapid drop cellular NAD(H) ATP contents, culminating 8-12 later in death. antagonists fully prevented nucleotide depletion Interestingly, early 60 min challenge with N-methyl-N'-nitro-N-nitrosoguanidine, mitochondrial...

10.1074/jbc.m414526200 article EN cc-by Journal of Biological Chemistry 2005-03-05

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTModulation of the Kynurenine Pathway in Search for New Neuroprotective Agents.Synthesis and Preliminary Evaluation (m-Nitrobenzoyl)alanine, a Potent Inhibitor Kynurenine-3-hydroxylaseRoberto Pellicciari, Benedetto Natalini, Gabriele Costantino, Mahmoud R. Mahmoud, Luisa Mattoli, Bahman M. Sadeghpour, Flavio Moroni, Alberto Chiarugi, Raffaella CarpenedoCite this: J. Med. Chem. 1994, 37, 5, 647–655Publication Date (Print):March 1, 1994Publication...

10.1021/jm00031a015 article EN Journal of Medicinal Chemistry 1994-03-01

The activation of nuclear factor kappa B (NF-κB) p50/RelA is a key event in ischemic neuronal injury, as well brain tolerance. We tested whether epigenetic mechanisms affecting the acetylation state RelA might discriminate between neuroprotective and neurotoxic NF-κB during ischemia. were investigated cortices mice subjected to preconditioning ischemia or lethal middle cerebral artery occlusion (MCAO) primary cortical neurons exposed oxygen-glucose deprivation (OGD). In MCAO OGD, activated...

10.1038/cddis.2010.76 article EN cc-by Cell Death and Disease 2010-11-04

Although still used by hundreds of millions people worldwide, the mechanism analgesic action pyrazolone derivatives (PDs), dipyrone, propyphenazone and antipyrine remains unknown. The transient receptor potential ankyrin 1 (TRPA1) channel, expressed nociceptors, is emerging as a major pain transduction pathway. We hypothesized that PDs target TRPA1 channel this produce their effect.Calcium responses currents were studied in cultured TRPA1-expressing rodent dorsal root ganglion neurons human...

10.1111/bph.13129 article EN British Journal of Pharmacology 2015-03-13
Coming Soon ...